Pancreatic Cancer Partnering 2009-2014

Date: March 1, 2014
Pages: 150
US$ 995.00
License [?]:
Publisher: CurrentPartnering
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), CD-ROM Mail Delivery, E-mail Delivery (Word)

Download PDF Leaflet

Pancreatic Cancer Partnering 2009-2014
The Pancreatic Cancer Partnering 2009-2014 provides understanding and access to the pancreatic cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of pancreatic cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pancreatic cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 80 links to online copies of actual pancreatic cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of pancreatic cancer partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in pancreatic cancer partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading pancreatic cancer deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of pancreatic cancer partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of pancreatic cancer technologies and products.

Report scope

Pancreatic Cancer Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to pancreatic cancer trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:
  • Trends in pancreatic cancer dealmaking in the biopharma industry since 2009
  • Access to summary headline, upfront, milestone and royalty data
  • Access to over 80 pancreatic cancer contract documents
  • The leading pancreatic cancer deals by value since 2009
In Pancreatic Cancer Partnering 2009-2014, the available deals are listed by:
  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Company A-Z
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.



2.1. Introduction
2.2. Pancreatic cancer partnering over the years
2.3. Bigpharma pancreatic cancer dealmaking activity
2.4. Pancreatic cancer partnering by deal type
2.5. Pancreatic cancer partnering industry sector
2.6. Pancreatic cancer partnering by stage of development
2.7. Pancreatic cancer partnering by technology type
2.8. Disclosed financial deal terms for pancreatic cancer
  2.8.1 Pancreatic cancer headline values
  2.8.2 Pancreatic cancer upfront payments
  2.8.3 Pancreatic cancer milestone payments
  2.8.4 Pancreatic cancer royalty rates


3.1. Introduction
3.2. Top pancreatic cancer deals by value
3.3. Top pancreatic cancer deals involving bigpharma


4.1. Introduction
4.2. Company A-Z
4.3. By deal type
  Asset purchase
  Bigpharma outlicensing
  Collaborative R&D
  Contract service
  Equity purchase
  Joint venture
  Spin out
4.4. By industry sector
  Drug delivery
  Medical device
  Generic pharma
  Research tools
  Specialty pharma
4.5. By stage of development
  Phase I
  Phase II
  Phase III
4.6. By technology type
  Animal models
  Biological compounds
  Cell culture
  Cell therapy
  Clinical testing
  Diagnostic - companion
  Discovery tools
  DNA probes
  Drug delivery
  Enabling technology
  Gene therapy
  Industrial chemicals
  In vitro models
  Monoclonal antibodies
  Personalised medicine
  Recombinant DNA
  Research services
  Research supplies
  RNA therapeutics
  Small molecules
  Stem cells


5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking


Appendix 1 – Deal type definitions


Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports


Figure 1: Pancreatic cancer partnering since 2009
Figure 2: Bigpharma – top 50 – pancreatic cancer deals 2009 to 2011
Figure 3: Bigpharma pancreatic cancer deal frequency – 2009 to 2011
Figure 4: Pancreatic cancer partnering by deal type since 2009
Figure 5: Pancreatic cancer partnering by industry sector since 2009
Figure 6: Pancreatic cancer partnering by stage of development since 2009
Figure 7: Pancreatic cancer partnering by technology type since 2009
Figure 8: Pancreatic cancer deals with a headline value
Figure 9: Pancreatic cancer deals with upfront payment values
Figure 10: Pancreatic cancer deals with milestone payments
Figure 11: Pancreatic cancer deals with royalty rates, %
Figure 12: Top pancreatic cancer deals by value since 2009
Figure 13: Top pancreatic cancer deals signed by bigpharma value since 2009
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions

Ask Your Question

Pancreatic Cancer Partnering 2009-2014
Company name*:
Contact person*:
Request invoice
Your enquiry: